scispace - formally typeset
Open AccessJournal ArticleDOI

Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.

TLDR
Treatment approaches to COVID‐19 treatment involve the use of antiviral agents that interfere with the SARS‐CoV‐2 lifecycle to prevent further viral replication and utilizing immunomodulators to dampen the immune system in order to prevent cytokine storm and tissue damage.
Abstract
SARS-CoV-2 is a novel human coronavirus responsible for the Coronavirus disease 2019 (COVID-19) pandemic. Pneumonia and acute respiratory distress syndrome are the major complications of COVID-19. SARS-CoV-2 infection can activate innate and adaptive immune responses and result in massive inflammatory responses later in the disease. These uncontrolled inflammatory responses may lead to local and systemic tissue damage. In patients with severe COVID-19, eosinopenia and lymphopenia with a severe reduction in the frequency of CD4+ and CD8+ T cells, B cells and natural killer (NK) cells are a common feature. COVID-19 severity hinges on the development of cytokine storm characterized by elevated serum levels of pro-inflammatory cytokines. Moreover, IgG-, IgM- and IgA-specific antibodies against SARS-CoV-2 can be detected in most patients, along with the viral RNA, forming the basis for assays that aid in patient diagnosis. Elucidating the immunopathological outcomes due to COVID-19 could provide potential targets for immunotherapy and are important for choosing the best clinical management by consultants. Currently, along with standard supportive care, therapeutic approaches to COVID-19 treatment involve the use of antiviral agents that interfere with the SARS-CoV-2 lifecycle to prevent further viral replication and utilizing immunomodulators to dampen the immune system in order to prevent cytokine storm and tissue damage. While current therapeutic options vary in efficacy, there are several molecules that were either shown to be effective against other viruses such as HIV or show promise in vitro that could be added to the growing arsenal of agents used to control COVID-19 severity and spread.

read more

Citations
More filters
Journal ArticleDOI

SARS-CoV-2 Infects Red Blood Cell Progenitors and Dysregulates Hemoglobin and Iron Metabolism

TL;DR: In this article , the authors demonstrate that SARS-CoV-2 directly infects erythroid precursor cells, impairs hemoglobin homeostasis and aggravates COVID-19 disease.
Journal ArticleDOI

Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients.

TL;DR: In this article, the authors found that positive APLA serology was associated with more severe disease regardless of COVID-19 status, while positive aCL was not associated with surrogate markers of thrombosis but ICL was strongly associated with worse disease severity and higher antinuclear antibodies (ANAs).
Journal ArticleDOI

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination.

TL;DR: In this article, the authors summarized the pathophysiological and thrombotic features of COVID-19 and the safety and efficacy of currently approved CoV-19 vaccines with an aim to clarify the recent concerns of thromboembolic events after CoV19 vaccination.
Journal ArticleDOI

COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes

TL;DR: This review outlines the putative signaling pathways at the interface of CO VID-19 and several diseases, emphasizing the clinical and molecular implications of concurring diseases in COVID-19 clinical outcomes.
Journal ArticleDOI

Reduction of Cardiac Autonomic Modulation and Increased Sympathetic Activity by Heart Rate Variability in Patients With Long COVID

TL;DR: The findings indicate that long COVID leads to sympathetic excitation influence and parasympathetic reduction, which can increase the heart rate and blood pressure and predispose to cardiovascular complications.
References
More filters
Journal ArticleDOI

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

TL;DR: The epidemiological and clinical characteristics of novel coronavirus (2019-nCoV)-infected pneumonia in Wuhan, China, and hospital-associated transmission as the presumed mechanism of infection for affected health professionals and hospitalized patients are described.
Journal ArticleDOI

A new coronavirus associated with human respiratory disease in China.

TL;DR: Phylogenetic and metagenomic analyses of the complete viral genome of a new coronavirus from the family Coronaviridae reveal that the virus is closely related to a group of SARS-like coronaviruses found in bats in China.
Related Papers (5)